Related Experiment Videos
Cardiomyopathy and heart failure in diabetes
1Section of Heart Failure and Cardiac Transplant Medicine, George M. and Linda H. Kaufman Center for Heart Failure, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Insights
Patients with type 2 diabetes and insulin resistance face high heart failure risks. Effective management requires specific drug choices, aggressive risk factor control, and further research into oral antidiabetic agents like TZDs.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Insulin resistance and type 2 diabetes significantly increase heart failure risk and worsen prognosis.
- Heart failure management in diabetic patients requires strategies to alter disease progression.
Purpose of the Study:
- To outline optimal drug selection for heart failure in patients with insulin resistance or type 2 diabetes.
- To emphasize the importance of risk factor modification and glycemic control.
- To highlight the need for further research on oral antidiabetic agents' cardiovascular impact.
Main Methods:
- Review of current pharmacological treatments for heart failure.
- Emphasis on guideline-recommended first-line agents.
- Discussion of risk factor management strategies.
Main Results:
- ACE inhibitors and beta-adrenergic blockers are recommended as first-line treatments.
- Aggressive modification of risk factors, blood pressure, and glycemic control are critical.
- The safety and efficacy of certain oral antidiabetic agents, particularly TZDs, require further investigation.
Conclusions:
- Heart failure treatment in diabetic patients necessitates a tailored approach focusing on disease modification.
- Established therapies like ACE inhibitors and beta-blockers are essential.
- More research is needed to define the role and safety of newer antidiabetic medications in cardiovascular outcomes.
Abstract:
Patients with insulin resistance or type 2 diabetes have a particularly high risk for heart failure and a poor prognosis once they develop heart failure. The choice of drugs for the management of heart failure in these patients should be directed at changing the natural history of the disease. The various drugs available for the treatment of heart failure, including ACE inhibitors and beta-adrenergic blockers, are known to be beneficial and should be given as first-line agents. Aggressive risk-factor modification and tight blood pressure and glycemic control are crucial. Much work is needed to establish the safety and efficacy of various oral antidiabetic agents, especially the TZDs, for which the theoretic benefits are substantial and overall morbidity and mortality impact remain ill-defined.